Synapse - Michael Morris

Results (588)

Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: Phase 3 CALGB 80802 randomized clinical trial

Journal Article

Abou-Alfa, G. K.; Shi, Q.; Knox, J. J.; Kaubisch, A.; Niedzwiecki, D.; Posey, J.; Tan, B. R. Jr; Kavan, P.; Goel, R.; Lammers, P. E.; more...
JAMA Oncology (2019)

Fulltext@MSK | Save

Comparison of magnetic resonance imaging-stratified clinical pathways and systematic transrectal ultrasound-guided biopsy pathway for the detection of clinically significant prostate cancer: A systematic review and meta-analysis of randomized controlled trials

Review

Woo, S.; Suh, C. H.; Eastham, J. A.; Zelefsky, M. J.; Morris, M. J.; Abida, W.; Scher, H. I.; Sidlow, R.; Becker, A. S.; Wibmer, A. G.; more...
European Urology Oncology (2019)

Fulltext@MSK | Save

Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics

Review

Rahbar, K.; Bodei, L.; Morris, M. J.
Journal of Nuclear Medicine (2019)

Fulltext@MSK | Save

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)

Meeting Abstract

Zhang, T.; Ballman, K. V.; Choudhury, A. D.; Chen, R. C.; Watt, C.; Wen, Y.; Zemla, T.; Emamekhoo, H.; Gupta, S.; Morris, M. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of (177)Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Sartor, A. O.; Morris, M. J.; Krause, B. J.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase Ill trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

Meeting Abstract

Rosenberg, J. E.; Ballman, K. V.; Halabi, S.; Watt, C.; Hahn, O. M.; Steen, P. D.; Dreicer, R.; Flaig, T. W.; Stadler, W. M.; Sweeney, C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Diagnostic performance of (18)F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of (18)F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC)

Meeting Abstract

Morris, M. J.; Durack, J. C.; Alva, A. S.; Vargas, H. A.; Piert, M.; Pachynski, R. K.; Pouliot, F.; Beauregard, J. M.; Preston, M. A.; Choudhury, A. D.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes

Meeting Abstract

Mota, J. M.; Barnett, E.; Nauseef, J.; Stopsack, K. H.; Wibmer, A. G.; Danila, D. C.; Rathkopf, D. E.; Slovin, S. F.; Kantoff, P. W.; Scher, H. I.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Morris, M. J.; Heller, G.; Bryce, A. H.; Armstrong, A. J.; Beltran, H.; Hahn, O. M.; McGary, E. C.; Mehan, P. T.; Goldkorn, A.; Roth, B. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

A phase Ill, multicenter study to assess the diagnostic performance and clinical impact of (18)F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR)

Meeting Abstract

Morris, M. J.; Pouliot, F.; Saperstein, L.; Rowe, S. P.; Gorin, M. A.; Josephson, D. Y.; Wong, J. Y. C.; Carroll, P.; Lin, T.; Stambler, N.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save